NeuroVive board selects Erik Kinnman as new CEO
pharmafile | February 23, 2016 | Appointment | |
Mitochondrial medicine specialist NeuroVive Pharmaceutical’s board of directors has selected Erik Kinnman as the company’s new chief executive, from March 14, 2016.
He succeeds interim chief executive Jan Nilsson, who will resume his position as chief operating officer at the company.
Kinnman is a seasoned life science executive with broad experience and understanding from the industry across a variety of businesses and functions. He has held a number of senior leadership positions in biopharmaceutical companies including AstraZeneca and Sobi. His expertise and experience includes clinical development, business strategy, business development, and investor relations.
Kinnman also has experience from the financial sector, holds an Executive MBA from the Stockholm School of Economics and has comprehensive scientific qualifications from the Karolinska Institutet, which has rendered him a Ph.D. and an associate professor.
“The NeuroVive Board and I are confident that Erik Kinnman is the right person to lead the company, its strategy, and leverage the opportunities. The combination of his strategic vision and medical expertise is an excellent fit with NeuroVive’s strategy refocused towards R&D. Erik Kinnman is a strong and experienced leader who has a proven ability to translate scientific, clinical and business strategy into execution,” comments Gregory Batcheller, chairman of the NeuroVive board of directors.
“He will provide expertise and focus across the organisation and establish solid partnerships that will enhance our R&D program further. His broad experience grounded in research, medicine and the biopharmaceutical industry is exactly what we need to lead this organisation forward.”
Eric Kinnman comments: “I am excited about NeuroVive, the CEO role, and the opportunity to contribute to the success and growth of the company. NeuroVive is a highly innovative organisation and I am convinced that it has great potential in its range of novel treatment opportunities and their commercial potential. NeuroVive and its partners are truly led by a purpose and passion to make a difference and meaningful impact to patients affected by mitochondrial disorders. I will enable our researchers and partners to deliver on the opportunities in the clinical projects, as well as in the early pipeline to drive the value of NeuroVive.”
